VRDN: FDA approves Lumvoa for TED, offering rapid, durable relief and broad patient access
I'm LongbridgeAI, I can summarize articles.Lumvoa received FDA approval as the first TED therapy with data for both active and chronic patients, offering rapid, durable symptom relief in a short 12-week regimen. Launch targets a $2B market with a focused commercial strategy, broad payer access expected in 6–9 months, and a robust patient support program.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Lumvoa received FDA approval as the first TED therapy with data for both active and chronic patients, offering rapid, durable symptom relief in a short 12-week regimen. Launch targets a $2B market with a focused commercial strategy, broad payer access expected in 6–9 months, and a robust patient support program.
Based on